Hydrocortisone Acetate

Summary

Hydrocortisone Acetate (CHEMBL1091) is an approved small molecule; indicated across 7 conditions including skin disorder and atopic eczema.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 7 conditions
• Clinical trials: 4
• Chemistry: 404.5 Da · C23H32O6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1091
Name	Hydrocortisone Acetate
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	5744
ChEBI	CHEBI:17609
Molecular formula	C23H32O6
Molecular weight	404.5
InChIKey	ALEXXDVDDISNDU-JZYPGELDSA-N

SMILES: CC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)O)C)O

IUPAC name: [2-[(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate

Also known as: Barquinol hc, Chloromycetin hydrocort, Colifoam, Cortef acetate, Cortifoam, Cortril, Cortucid, Dricort, Epifoam, Framycort, Fucidin h, Genticin hc

Patent coverage: 17,046 distinct patent families (45,061 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 7 (assay-derived). Sample: Prelamin-A/C, Androgen receptor, Beta-lactamase, Progesterone receptor, Muscarinic acetylcholine receptor M1, Corticosteroid-binding globulin, Hypoxia-inducible factor 1-alpha.

Bioactivity

ChEMBL activities: 6 potent at pChembl ≥ 5 of 9 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
SERPINA6	7.55	Ki	28.18	nM	CHEMBL_ACT_953949
LMNA	7.5	Potency	31.6	nM	CHEMBL_ACT_3651033
HIF1A	6.9	Potency	125.9	nM	CHEMBL_ACT_4132708
HIF1A	6.9	Potency	125.9	nM	CHEMBL_ACT_4519477
AR	5.42	AC50	3808	nM	CHEMBL_ACT_25203697
PGR	5.12	AC50	7672	nM	CHEMBL_ACT_25204630

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

7 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
skin disorder	4	MONDO:0005093	EFO:0000701
atopic eczema	2	MONDO:0004980	EFO:0000274
hemorrhoid	2	MONDO:0004872	EFO:0009552
vitiligo	1	MONDO:0008661	EFO:0004208
depressive disorder	0	MONDO:0002050	MONDO:0002050

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE2	2
PHASE1	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00220454	PHASE2	COMPLETED	Effect of Estrogen & Stress for Postmenopausal Women
NCT02689856	PHASE2	COMPLETED	Safety and Efficacy of Hydrocortisone and Lidocaine Treatment of Grade I and II Hemorrhoids
NCT02671058	PHASE1	COMPLETED	Pharmacokinetics and Bioavailability of Hydrocortisone Acetate Suppositories
NCT02837432	EARLY_PHASE1	COMPLETED	The Effect of Cortisol Administration on Neural Correlates of Emotion in Depression

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).